Literature DB >> 20534382

Effect of transient receptor potential vanilloid 1 (TRPV1) receptor antagonist compounds SB705498, BCTC and AMG9810 in rat models of thermal hyperalgesia measured with an increasing-temperature water bath.

Valéria Tékus1, Kata Bölcskei, Agnes Kis-Varga, László Dézsi, Eva Szentirmay, András Visegrády, Csilla Horváth, János Szolcsányi, Gábor Petho.   

Abstract

The transient receptor potential vanilloid 1 (TRPV1) receptor is activated by noxious heat, various endogenous mediators and exogenous irritants. The aim of the present study was to compare three TRPV1 receptor antagonists (SB705498, BCTC and AMG9810) in rat models of heat hyperalgesia. The behavioural noxious heat threshold, defined as the lowest temperature evoking nocifensive reaction, was measured with an increasing-temperature water bath. The effects of TRPV1 receptor antagonists were assessed in thermal hyperalgesia induced by the TRPV1 agonist resiniferatoxin (RTX), mild heat injury (51 degrees C, 20s) or plantar incision in rats. The control heat threshold was 43.2+/-0.4 degrees C. RTX induced an 8-10 degrees C decrease in heat threshold which was dose-dependently inhibited by oral pre-treatment with any of the TRPV1 receptor antagonists with a minimum effective dose of 1mg/kg. The mild heat injury-evoked 7-8 degrees C heat threshold drop was significantly reversed by all three antagonists injected i.p. as post-treatment. The minimum effective doses were as follows: SB705498 10, BCTC 3 and AMG9810 1mg/kg. Plantar incision-induced heat threshold drop (7-8 degrees C) was dose-dependently diminished by an oral post-treatment with any of the antagonists with minimum effective doses of 10, 3 and 3mg/kg, respectively. Assessment of RTX hyperalgesia by measurement of the paw withdrawal latency with a plantar test apparatus yielded 30 mg/kg minimum effective dose for each antagonist. In conclusion, measurement of the noxious heat threshold with the increasing-temperature water bath is suitable to sensitively detect the effects of TRPV1 receptor antagonists in thermal hyperalgesia models. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20534382     DOI: 10.1016/j.ejphar.2010.05.052

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

Review 1.  TRPV1 and SP: key elements for sepsis outcome?

Authors:  Jennifer Victoria Bodkin; Elizabeth Soares Fernandes
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 2.  TRP channels: a journey towards a molecular understanding of pain.

Authors:  Tamara Rosenbaum; Sara L Morales-Lázaro; León D Islas
Journal:  Nat Rev Neurosci       Date:  2022-07-13       Impact factor: 38.755

3.  Neonatal capsaicin treatment in rats induces chronic hyperthermia resulting in infectious disease.

Authors:  Keun-Yeong Jeong; Hwan Mook Kim
Journal:  Exp Ther Med       Date:  2015-10-23       Impact factor: 2.447

4.  Effect of cannabidiolic acid and ∆9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain.

Authors:  Erin M Rock; Cheryl L Limebeer; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2018-09-17       Impact factor: 4.530

5.  Does intraoperative remifentanil infusion really make more postoperative pain?

Authors:  Ji-Seon Son; Seonghoon Ko
Journal:  Korean J Anesthesiol       Date:  2011-09-23

6.  TRPV1 antagonist attenuates postoperative hypersensitivity by central and peripheral mechanisms.

Authors:  Eva Uchytilova; Diana Spicarova; Jiri Palecek
Journal:  Mol Pain       Date:  2014-11-17       Impact factor: 3.395

Review 7.  TRPs in Pain Sensation.

Authors:  Isaac Jardín; José J López; Raquel Diez; José Sánchez-Collado; Carlos Cantonero; Letizia Albarrán; Geoffrey E Woodard; Pedro C Redondo; Ginés M Salido; Tarik Smani; Juan A Rosado
Journal:  Front Physiol       Date:  2017-06-09       Impact factor: 4.566

8.  Elevated expression of transient receptor potential vanilloid type 1 in dorsal root ganglia of rats with endometriosis.

Authors:  Yu-Ling Lian; Ming-Jun Cheng; Xian-Xia Zhang; Li Wang
Journal:  Mol Med Rep       Date:  2017-06-15       Impact factor: 2.952

9.  Vascular Endothelial Growth Factor (VEGF) Induced Downstream Responses to Transient Receptor Potential Vanilloid 1 (TRPV1) and 3-Iodothyronamine (3-T1AM) in Human Corneal Keratocytes.

Authors:  Ersal Türker; Fabian Garreis; Noushafarin Khajavi; Peter S Reinach; Pooja Joshi; Tobias Brockmann; Alexander Lucius; Nina Ljubojevic; Elizabeth Turan; Drew Cooper; Felix Schick; Rob Reinholz; Uwe Pleyer; Josef Köhrle; Stefan Mergler
Journal:  Front Endocrinol (Lausanne)       Date:  2018-11-22       Impact factor: 5.555

10.  The Heat Sensing Trpv1 Receptor Is Not a Viable Anticonvulsant Drug Target in the Scn1a +/- Mouse Model of Dravet Syndrome.

Authors:  Vaishali Satpute Janve; Lyndsey L Anderson; Dilara Bahceci; Nicole A Hawkins; Jennifer A Kearney; Jonathon C Arnold
Journal:  Front Pharmacol       Date:  2021-05-17       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.